F S&P 500
5,241.25 +2.25 (+0.04%) F Dow Jones
39,570.00 +34.00 (+0.09%) F Nasdaq
18,217.50 +3.00 (+0.02%) E-mini Russell 2000 Index Futur
2,085.00 +0.90 (+0.04%) Petróleo
79.78 +0.52 (+0.66%) Oro
2,359.70 +19.40 (+0.83%)
Avidity Biosciences, Inc. (RNA)
Fuera de horario:
Avidity Biosciences, Inc.
10578 Science Center Drive
Suite 125
San Diego, CA 92121
United States
858 401 7900
https://www.aviditybiosciences.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 253
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Troy Edward Wilson J.D., Ph.D. | Co-Founder & Independent Chairman | 70k | N/D | 1969 |
| Ms. Sarah Boyce | President, CEO & Director | 998.88k | 1.16M | 1972 |
| Mr. Michael F. MacLean | Chief Financial & Chief Business Officer | 674.74k | N/D | 1966 |
| Dr. W. Michael F. Flanagan Ph.D. | Chief Scientific & Technical Officer | 675.22k | N/D | 1963 |
| Ms. Teresa McCarthy | Chief Human Resources Officer | 628.79k | N/D | 1964 |
| Dr. Arthur A. Levin Ph.D. | Distinguished Scientist, Strategic Leader & Director | 304.69k | 433.87k | 1954 |
| Mr. Eric B. Mosbrooker | Chief Strategy Officer | 45k | N/D | 1967 |
| Prof. Mark E. Davis Ph.D. | Scientific Founder, Member of Scientific Advisory Board and Member of Board of Managers | N/D | N/D | N/D |
| Dr. Frank P. McCormick Ph.D. | Scientific Founder & Member of Scientific Advisory Board | N/D | N/D | 1950 |
| Mr. Geoffrey M. Grande C.F.A. | VP of Investor Relation & Corporate Communication | N/D | N/D | N/D |
Descripción
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
Gestión corporativa
La calificación ISS Governance QuickScore de Avidity Biosciences, Inc. a partir del 1 de mayo de 2024 es 9. Las puntuaciones principales son Auditoría: 9; Junta: 9; Derechos del accionista: 8; Compensación: 8.
